Following AAV9-CAG-Galns treatment, MPSIVA rats showed full correction of skeletal dysplasia, indicating the superior advantage of widespread transduction of skeletal and non-skeletal tissues to correct MPSIVA disease. This evidence concerns the gene GALNS and mucopolysaccharidosis type 4A.